Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
AMSTERDAM, the Netherlands, March 2, 2016 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen & Company Healthcare Conference to be held on March 7 – 9, 2016 at the Boston Marriott Copley Place, Boston, Massachusetts.
Date: March 9, 2016
Time: 11:20 a.m. EST / 5:20 p.m. CET
Speaking for uniQure: Daniel Soland (Chief Executive Officer)
The live webcast, including a slide presentation, can be accessed through the following link: http://wsw.com/webcast/cowen30/qure or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Eva Mulder
Direct : +31 20 240 6103
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
